KKR Genetic Disorder L.P. - 12 May 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: 10%+ Owner
Issuer ticker: BBIO
Reported as of: 12 May 2025
Net transaction value: -$205,200,000
SEC form: 4
Accepted by SEC: 14 May 2025, 17:24:23 UTC
Prior SEC filing: 07 Mar 2025
Source filing: View source filing
Reporting owner signature: See Exhibit 99.1

Key filing fact

KKR Genetic Disorder L.P. filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 14 May 2025.

Key facts

This page summarizes KKR Genetic Disorder L.P.'s Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 May 2025, 17:24.

Change

Previous filing in this sequence was filed on 07 Mar 2025.
Current net transaction value: -$205,200,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (9)

CIK 0001780408 Primary reporting owner

KKR Genetic Disorder L.P.

Relationship: 10%+ Owner
Address: 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001780428

KKR Genetic Disorder GP LLC

Relationship: 10%+ Owner
Address: 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001472698

KKR Group Partnership L.P.

Relationship: 10%+ Owner
Address: 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001743754

KKR Group Holdings Corp.

Relationship: 10%+ Owner
Address: 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001932162

KKR Group Co. Inc.

Relationship: 10%+ Owner
Address: 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001404912

KKR & Co. Inc.

Relationship: 10%+ Owner
Address: 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001472694

KKR Management LLP

Relationship: 10%+ Owner
Address: 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001081714

KRAVIS HENRY R

Relationship: 10%+ Owner
Address: C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

CIK 0001081715

ROBERTS GEORGE R

Relationship: 10%+ Owner
Address: C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK
Signature: See Exhibit 99.1
Signature date: 14 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Sale

Transaction value: $205,200,000
Shares: -6,000,000
Change %: -31%
Price: $34.20
Shares after: 13,260,971
Date: 12 May 2025
Ownership: See footnotes
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

KKR Genetic Disorder L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the "Issuer"), par value $0.001 per share (the "Common Stock"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $34.20 pursuant to Rule 144 of the Securities Act of 1933, as amended.

Footnote F2

The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities.

Footnote F3

Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.